Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tevogen Bio HoldingsFRA:G280 10 EPS without NRI is €-5.76 as of Mar. 2026. GuruFocus rates FRA:G280 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,168 Biotechnology companies, Tevogen Bio Holdings ranks worse than 85616.35% on this metric.
Tevogen Bio Holdings's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-1.40.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.76.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Tevogen Bio Holdings's EPS without NRI or its related term are showing as below:
During the past 5 years, Tevogen Bio Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 54.30% per year. The lowest was 54.30% per year. And the median was 54.30% per year.
FRA:G280's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.4 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Tevogen Bio Holdings's EPS (Basic) for the
three
months ended in Mar. 2026 was €-1.39.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.75.
Tevogen Bio Holdings (FRA:G280) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Tevogen Bio Holdings EPS without NRI Related Terms
Tevogen Bio Holdings EPS without NRI Historical Data
* Premium members only.
The historical data trend for Tevogen Bio Holdings's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:G280 vs GRDX, DYAI, KYNB: EPS without NRI Comparison
For the Biotechnology subindustry, Tevogen Bio Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tevogen Bio Holdings PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tevogen Bio Holdings's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Tevogen Bio Holdings's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tevogen Bio Holdings (FRA:G280) has a EPS without NRI of €-5.76 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Tevogen Bio Holdings and its competitors. According to the industry distribution chart, Tevogen Bio Holdings ranks #999999 out of 1168 companies in the Biotechnology industry.
Is Tevogen Bio Holdings' EPS without NRI too high?
Tevogen Bio Holdings' current EPS without NRI is €-5.76. Based on the distribution chart, Tevogen Bio Holdings ranks #999999 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tevogen Bio Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tevogen Bio Holdings' EPS without NRI compare to GRDX and DYAI?
According to the Biotechnology industry distribution chart, Tevogen Bio Holdings ranks #999999 out of 1168 companies for EPS without NRI. This places Tevogen Bio Holdings in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Tevogen Bio Holdings and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tevogen Bio Holdings's current EPS without NRI is €-5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tevogen Bio Holdings stock overvalued right now?
Tevogen Bio Holdings (FRA:G280) has a current EPS without NRI of €-5.76. The current EPS without NRI is €-5.76. Tevogen Bio Holdings' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Tevogen Bio Holdings (FRA:G280), the current EPS without NRI is €-5.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
10GF Score
Get the complete analysis for FRA:G280
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G280 has been successfully added to your 
